<DOC>
	<DOCNO>NCT02935998</DOCNO>
	<brief_summary>1 . The title study multi-center , non randomize , open-labeled , intervention study : efficacy safety intramuscular ziprasidone three day patient acute psychotic agitation . 2 . The primary objectiveis evaluate efficacy intramuscular ziprasidone patient acute psychotic agitation daily clinical practice . 3 . The secondary objective are:1.To evaluate safety intramuscular ziprasidone patient acute psychotic agitation daily clinical practice.2.To compare efficacy tolerance intramuscular ziprasidone patient agitation different psychotic disorder 3.To compare efficacy tolerance intramuscular ziprasidone patient first episode andmulti-episode patient . 4.To explore measure base administration accord severity symptoms.5.To compare efficacy tolerance ziprasidone im monotherapy combination antipsychotic drug clinical practice . 4 . The Rationale : In China , study ziprasidone im treat agitation focus schizophrenia . But foreign country , ziprasidone im also approve treat psychotic agitation , include bipolar schizoaffective disorder . And clinical practice China , ziprasidone im also use treat patient , although evidence less . In study , assume ziprasidone im treat psychotic agitation effective safe . 5 . Study population : The study plan enroll 1000 subject China . （6）The background hypothesis：The research ziprasidone mesylate injection country concentrate schizophrenia present , foreign country ziprasidone approve psychotic agitation , include mania etc . It 's also use substance abuse alcohol induce agitation.Therefore , study assume ziprasidone mesylate injection effective treatment acute agitation , 's well tolerate .</brief_summary>
	<brief_title>The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation</brief_title>
	<detailed_description>1 . Trial Design : This multi-center , open-labeled , intervention study . 2 . STUDY EVALUATION：1 ) Primary efficacy endpoint：The change BARS total score baseline endpoint.2 ) Secondary efficacy endpoint： - The change CGI-S baseline endpoint - The change BARS/CGI-S/CGI-I baseline every visit - The percentage response end 2h ( BARS decrease score &gt; =2 ) - Subgroup analysis : ( 1 ) Comparison difference reduction BARS/CGI-S different disease subgroup . ( 2 ) Comparison difference reduction BARS/CGI-S first episode multi-episode patient . ( 3 ) Comparison difference reduction BARS/CGI-S different previous antipsychotic treatment . ( 4 ) Comparison difference disease category , dosage , duration , reduction BARS/CGI-S monotherapy combination oral antipsychotic drug Safety evaluation 3 ) Include adverse event , ECG ( change rate ECG average change QT ) , vital sign baseline endpoint . 1 . The change Simpson-Angus baseline endpoint . 2 . The incidence ADR、extrapyramidal symptoms、tachycardia studyThe incidence study . 3 . STUDY DRUGS : The injection mesylate ziprasidone use study market , manufacture Pfizer provide study drug research purposes.Strength : Each vial contain Ziprasidone 30 mg , Sulfobutyl betadex sodium 441 mg . When reconstitute direct solution injection contain equivalent 20 mg per mL Ziprasidone.Ziprasidone intramuscular intend intramuscular use administer intravenously . 4 . DATA ADMINISTRATION AND STATISTICAL METHODS : The case report form ( CRF ) use clinical study paper form . The data statistical analysis collect study record statistical analysis program ( SAP ) . 5 . Basic principle research design : Collecting safety , effectiveness index process drug treatment , analysis change 3 day treatment , record injection process study , order analyze safety efficacy injection ziprasidone real clinical practice .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Subjects must meet follow criterion enrol study : Male female subject age 1865 year Inpatients outpatient meet diagnostic criterion schizophrenia , schizoaffective disorder , Bipolar disorder manic feature mixed feature accord ICD10 BARS score &gt; = 5 baseline； Female subject must effective mean contraception ( example , oral prescription contraceptive , contraceptive , intrauterine device , male partner sterilization , etc . ) screen phase whole duration study ; Subjects comply visit plan , treatment , laboratory examination research program ; Subjects legal representative understand content research , agree participate sign write informed consent date . Subjects meet follow criterion exclude study : Have major unstable cardiovascular ( especially arrhythmia ) , respiratory , nervous system , include epilepsy obvious cerebrovascular disease ) , kidney , liver , endocrine , immune disease relate illness Have myocardial infarction decompensated heart failure recently Confirmed clinically significant abnormal laboratory value Clinically significant ECG abnormality Subjects history QTc prolongation predrug QTc 450 msec great Subjects serum K+ Mg2+ normal range A history malignant syndrome tardive dyskinesia history Concomitant use drug may induce QTc prolongation study , Sotalol , quinidine , amiodarone , erythromycin , clozapine clomipramine Known allergy ziprasidone product ingredient Pregnant lactate woman decide pregnant 3 month Use antipsychotic agent within 12 hour parenteral benzodiazepine within 4 hour prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>agitation</keyword>
	<keyword>ziprasidone</keyword>
</DOC>